RTHawk vs syngo MBF
Similar category, different focus. These tools serve overlapping but distinct needs.
Comparability 65/100
Comparability is an AI-graded 0–100 score of how directly these two tools compete — higher means a more apples-to-apples comparison.
AI Verdict
While both RTHawk and syngo MBF are FDA-cleared AI tools for cardiac diagnostics, they cater to different imaging modalities. RTHawk streamlines and enhances cardiac MRI acquisition and analysis, providing insights into ventricular function and flow. In contrast, syngo MBF specializes in quantitative myocardial blood flow analysis using PET imaging, offering specific metrics like MBF and MFR.
Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Frequently Asked Questions
RTHawk is designed to simplify and accelerate cardiac MRI acquisition with one-click automation, integrating with existing MRI scanners and appearing as an additional pulse sequence in the GE protocol. Syngo MBF is integrated within the syngo.via platform, which offers workflows adaptable to clinical needs and leverages AI for workflow acceleration in PET imaging analysis. Both platforms aim to streamline reporting, with syngo.via supporting HL7-based report export and integrating results into the EHR in a machine-readable format.
RTHawk utilizes an artifact detection neural network to identify suboptimal image quality and AI assistance to optimize inversion time, providing preliminary measures of left ventricular function like ejection fraction, volumes, and mass. Syngo MBF is AI-enhanced for quantitative myocardial blood flow (MBF) analysis, supporting dynamic Rubidium-PET and Ammonia-PET images, and includes motion compensation and residual activity correction. Studies have shown good to excellent reproducibility for MBF and MFR values with syngo MBF, though it may provide slightly lower MFR values than other software packages.
RTHawk focuses on enhancing cardiac MRI acquisition and analysis, offering real-time, free-breathing, and breath-hold sequences for improved patient access and efficiency in evaluating ischemia, ventricular function, and myocardial viability. Syngo MBF specializes in quantitative myocardial blood flow and myocardial flow reserve analysis using PET imaging, which is valuable for evaluating coronary artery disease, assisting in diagnosis, treatment, and risk stratification. These tools are largely complementary, addressing different imaging modalities and specific diagnostic questions within cardiology.
RTHawk emphasizes 'one-click automation' and simplifies cardiac MRI acquisition, potentially reducing the learning curve for technologists and allowing for faster exam times (e.g., cardiac ischemia exam in less than 15 minutes). Syngo MBF, integrated within the syngo.via platform, leverages AI for workflow acceleration and automation, which can lead to significant workflow efficiency gains and faster reading times, especially for users already familiar with the syngo.via ecosystem.
RTHawk is deployed on-premise and integrates with existing MRI scanners, implying site-specific integration with each MRI machine. Syngo MBF can be deployed on-premise with dedicated hardware or in virtualized environments, offering more flexibility for multi-site infrastructure planning and integration within the syngo.via platform, which supports multi-site deployments and data sharing across care teams. Multi-site deployments generally require careful consideration of network infrastructure, data synchronization, and consistent configuration across facilities.